Trial · NCT06782048
Use of Pyrvinium to Reverse Stomach Precancerous Conditions
NCT06782048, Phase 2, Not yet recruiting, National University Hospital, Singapore
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Use of Pyrvinium to Reverse Stomach Precancerous Conditions. Trials, record NCT06782048. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06782048
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Use of Pyrvinium to Reverse Stomach Precancerous Conditions
- NCT number
- NCT06782048
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- National University Hospital, Singapore
- Conditions
- STOMACH NEOPLASM
- Interventions
- Placebo, Pyrvinium, Blood biomarkers analyses, Oesophagogastroduodenoscopy (OGD) and biopsy, Gastric juice, saliva and stool collection and analyses
- First posted
- 2025-01-17
- Last updated
- 2026-10-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Histological Regression of GIM: Average percentage change of GIM in the antrum and corpus, as measured by histological evaluation of gastric biopsies at baseline and the study endpoint | Baseline, 6 weeks post-treatment | |
| Secondary | Surface Area of GIM Involvement: Measured in real-time using AI-guided imaging technology during endoscopy | During endoscopy at baseline, Day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment | |
| Secondary | Safety: Number of participants with treatment-related adverse events | From Day 1 to Day 14 of treatment | |
| Secondary | Efficacy in Patient-Derived Gastroids: Changes in phosphorylation levels of proteins in pre-cancerous gastroids derived from participants with GIM or dysplasia | Baseline | A maximum of 18 research biopsies will be taken at the baseline endoscopy, of which 4 biopsies of areas of known gastric IM will be used to generate gastric organoids. |
| Secondary | Efficacy in Patient-Derived Gastroids: Evaluation of growth and proliferation after pyrvinium treatment via imaging, staining and histological techniques | Baseline | A maximum of 18 research biopsies will be taken at the baseline endoscopy, of which 4 biopsies of areas of known gastric IM will be used to generate gastric organoids. |
| Secondary | Mechanistic Insights into Pyrvinium Action: Gene expression profiles (e.g., mucins MUC1, MUC2, MUC5AC) in biopsied gastric samples obtained during endoscopy | Baseline, Day 7, 6 weeks post-treatment, 1 year post-treatment | |
| Secondary | Serum Biomarkers for Gastric Cancer Risk: Levels of serum biomarkers such as TFF3, a known marker for gastric IM, measured via ELISA | Baseline, Day 7 of treatment, 6 weeks post-treatment, 1 year post-treatment | |
| Secondary | Impact on Gastric Microbiome: Changes in gastric microbiome composition post-treatment, analyzed using advanced sequencing methods | Baseline, 6 weeks post-treatment, 1 year post-treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06782048
GET https://conductscience.org/api/trials/v1/NCT06782048/registered